RU2847292C1 - Method of treating recurrent genital herpes in women of fertile age - Google Patents

Abstract

FIELD: medical science.

SUBSTANCE: invention refers to medicine, namely to immunology and dermatovenereology. Meglumine acrydonacetate Cycloferon is administered orally 300 mg 2 times a week with the simultaneous introduction of Superlymph porcine leukocyte peptide-protein complex 10 thousand units in 1 suppository intravaginally 2 times a week. That is combined with administering the anti-herpetic vaccine Vitagerpavac once a week No. 5 twice a year to recover the virus-specific immune response and form immunological memory cells. For the purpose of controlling the frequent HSVI, the virus suppression therapy with valaciclovir (Valtrex) 500 mg (1 tablet) is used once a day daily.

EFFECT: method provides higher clinical effectiveness in the form of reducing a rate of recurrent genital herpes, their length and severity ensured by the staged treatment according to the presented method.

1 cl, 1 ex

Description

The invention relates to medicine, in particular to clinical immunology and dermatovenereology, and can be used to treat women of childbearing age suffering from frequent episodes of genital herpes.

Frequent episodes of genital herpes simplex virus infection (HSV) in women of childbearing age negatively impact their health, as they trigger the development of chronic inflammatory diseases of the reproductive systems and pelvic organs, leading to post-infectious asthenic syndromes and asthenodepressive conditions that significantly reduce quality of life. The treatment of frequent recurrences of HSV in women of childbearing age is also a pressing issue due to the high prevalence of this disease (11-14%) and its negative impact on reproductive health.

A method for treating frequent recurrences of genital herpes (GH) is known using virus-suppressing therapy with atypical nucleoside drugs (1, 2, 3,6, 7, 8).

The disadvantage of this known method is its low efficiency due to the resumption of exacerbations immediately or shortly after discontinuation of the drug.

The closest method in terms of the technical result achieved is the treatment of frequent relapses of HSV, the genital form, using an antiherpetic vaccine (4, 5).

The disadvantage of the known method is its low efficiency due to the predominant effect on the specific systemic immune response and the lack of a point of application to the immunorehabilitation of the local representation of the immune system - lymphoid formations associated with the mucous membranes and skin of the urogenital area.

The authors proposed a highly effective method for treating women of childbearing age suffering from frequent recurrences of genital herpes simplex virus infection, which allows for the relief of both frequent and long-term episodes of this disease.

The technical result of the claimed method is an increase in the effectiveness of treatment in the form of a reduction in the frequency of relapses of genital herpes, their duration and severity due to the step-by-step treatment according to the scheme of the claimed method.

The technical result is achieved by systemic oral administration of an interferonogen in the form of meglumine acridonacetate (Cycloferon 300 mg, 2 tablets twice weekly), which induces the synthesis of anti-inflammatory cytokines and stimulates the antiviral integral cell-mediated immune response. This is accompanied by the simultaneous administration of a peptide-protein complex of porcine leukocytes (Superlymph 10 U, 1 suppository) intravaginally twice weekly for the immunorehabilitation of local lymphoid formations associated with skin and mucous membranes. The antiherpes vaccine (Vitagerpavak No. 5) is simultaneously administered once a week, twice a year, to restore the virus-specific immune response and form immunological memory cells. To control recurrent HSV infection, virus-suppressing therapy with valacyclovir (Valtrex 500 mg, one tablet once daily) was used. The treatment goal was defined as the time when no relapses were recorded during the last three months of therapy.

The method is carried out as follows.

Women of childbearing age who suffer from frequent episodes of genital herpes simplex virus infection type 1 or 2 are prescribed the following treatment regimen.

Oral administration of meglumine acridonacetate (Cycloferon 300 mg, 2 tablets) is administered twice weekly with the simultaneous administration of a peptide-protein complex of porcine leukocytes (Superlymph 10 U, 1 suppository intravaginally twice weekly) and an antiherpetic vaccine (Vitaherpavac No. 5) once a week twice a year, along with virus-suppressive therapy with valacyclovir (Valtrex 500 mg, 1 tablet once daily) until no episodes of disease exacerbation have been recorded over the last 3 months of therapy. Once the target indicator is achieved, anti-relapse therapy is discontinued.

Eleven patients were treated using the claimed method, with a good effect in five of them. Eleven patients aged 19-43, each of whom had experienced 6 to 10 episodes of HSVI types 1 or 2 of the genital form in the previous year, were treated for 12 months. The total number of HSVI episodes in the study group in the year preceding treatment was 83 episodes (7.5 on average) and 46 (4.1) days. Over the course of one year of treatment, the claimed method reduced both the number of HSVI recurrences (45 (4.1)) and their duration (21 (1.9) days). In five women, the target was achieved within one year.

Clinical example

Treatment was carried out according to the stated method.

Nadezhda 3., 35 years old, with a clinical diagnosis: Herpes simplex virus type 2 infection, with frequent relapses, genital form.

She complained of frequent recurring episodes of genital herpes - up to 10 times over the past year, lasting up to 7 days with sensations of pain and burning at the sites of rashes in the form of grouped vesicles on a hyperemic background, as well as general weakness and lethargy during this period.

Frequent episodes of genital herpes have been noted over the past 2 years, attributing them to community-acquired pneumonia and emotional stress.

On examination, the patient's condition is generally satisfactory, with little impairment of well-being. Noteworthy are brisk tendon reflexes in the upper and lower extremities (D=S) with expanded reflexogenic zones. The rest of the somatic status is unremarkable. Status Localis: a hyperemic, edematous plaque with grouped vesicles with an umbilicated depression in the center, occupying part of the smooth skin of the labia majora and the left vulval mucosa. Some of the vesicles have transformed into shallow, painful erosions surrounded by a red rim, while others are covered with brownish-yellow crusts. Several foci of hyperpigmentation are visible at the sites of previous relapses. Serodiagnosis with genotyping: HSV type 2.

The therapy was carried out according to the stated method.

An oral preparation of meglumine acridonacetate - Cycloferon 300 mg, 2 tablets twice a week (Monday and Thursday) was prescribed and taken with the simultaneous administration of a peptide-protein complex of porcine leukocytes - Superlymph 10 U, 1 suppository intravaginally twice a week (Tuesday, Friday) and an antiherpetic vaccine - Vitagerpavak No. 5 once a week, twice a year (autumn, spring), against the background of virus-suppressive therapy with valacyclovir - Valtrex 500 mg, 1 tablet once a day daily. In the first 3 months, the patient had 2 episodes of HH lasting from 3 to 5 days, in the next 6 months 2 episodes of HH, lasting 2-3 days, and in the last 3 months of the current year, no manifestations of HH were noted and the therapy was discontinued. The patient experienced 4 relapses of VPHI (a decrease in the number of episodes) of short duration over the course of a year, and, in addition, her asthenic disorders disappeared.

Thus, the treatment provided to the patient led to both a reduction in the number of relapses of GH to an acceptable level and a decrease in their duration, with the relief of asthenodepressive syndrome, which was accompanied by the disappearance of general weakness and lethargy.

The proposed method for treating genital herpes in women of childbearing age has demonstrated high efficacy, reducing both the number and duration of HSVI episodes.

Bibliography

1. Bebneva T.N., Khamoshina M.B., Tulupova M.S., Orazmuradov A.A., Orazov M.R., Abitova M.Z. Genital herpes in the practice of a gynecologist: complex questions - simple answers // Obstetrics and gynecology: news, opinions, training. 2019. Vol. 7, No. 3. P. 112-11.

2. Belousova T.A., Goryachkina M.V. Etiotropic therapy of herpes simplex: focus on valacyclovir // RMJ. 2015. T 9, 520-525.

3. Dvoryankova E.V., Sakaniya L.R., Babaev O.R., Shakhzadov V.V., Korsunskaya I.M. // Features of genital herpes in women. Gynecology. 2018. Vol. 20, No. 4. P. 55-59.

4. Melekhina E.V., Soldatova E.Yu., Muzyka A.D., Ponezheva Zh.B. Vaccine therapy of the herpes simplex virus: from past to present - where are we? Literature review // RMJ. 2021. TZ. P. 10.

5. Melekhina E.V., Soldatova E.Yu., Muzyka A.D., Ponezheva Zh.B. Vaccine therapy of the herpes simplex virus: from past to present - where are we? Literature review // RMZh.2021. No. 10, pp. 3-10.

6. Pestrikova T.Yu., Yurasova E.A., Yurasov I.V., Kotelnikova A.V. Basic principles of managing patients with genital herpes // Gynecology. 2019. Vol. 21, No. 1. P. 80-85.

7. Pestrikova T.Yu., Yurasova E.A., Yurasov I.V., Kotelnikova A.V. Modern aspects of tactics for genital herpes virus infection: a literature review // Gynecology. 2018. Vol. 20, No. 2. P. 67-73.

8. Shulzhenko A.E., Zuikova I.N., Shchubelko R.V. Recurrent herpes virus infection: strategy of antiviral therapy // Clinical dermatology and venereology. 2015. Vol. 14, No. 3. P. 29-36.

Claims (1)

A method for treating recurrent genital herpes in women of childbearing age, characterized in that it includes oral administration of meglumine acridonacetate Cycloferon 300 mg, 2 tablets 2 times a week, with the simultaneous administration of a peptide-protein complex of porcine leukocytes Superlymph 10 U, 1 suppository intravaginally 2 times a week and the antiherpetic vaccine Vitagerpavak No. 5 once a week 2 times a year, against the background of virus-suppressive therapy with valacyclovir Valtrex 500 mg, 1 tablet 1 time per day daily for a period when no relapse of the disease has been recorded over the last 3 months of therapy.